Postmarketing surveillance--lack of vigilance, lack of trust

Editorial

Phil B Fontanarosa et al. JAMA. 2004.

. 2004 Dec 1;292(21):2647-50.

doi: 10.1001/jama.292.21.2647. Epub 2004 Nov 22.

No abstract available

Comment on

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Graham DJ, et al. JAMA. 2004 Dec 1;292(21):2585-90. doi: 10.1001/jama.292.21.2585. Epub 2004 Nov 22. JAMA. 2004. PMID: 15572716
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.
Psaty BM, Furberg CD, Ray WA, Weiss NS. Psaty BM, et al. JAMA. 2004 Dec 1;292(21):2622-31. doi: 10.1001/jama.292.21.2622. Epub 2004 Nov 22. JAMA. 2004. PMID: 15572720 Review.
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.
Strom BL. Strom BL. JAMA. 2004 Dec 1;292(21):2643-6. doi: 10.1001/jama.292.21.2643. Epub 2004 Nov 22. JAMA. 2004. PMID: 15572722 No abstract available.
Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis".
Piorkowski JD Jr. Piorkowski JD Jr. JAMA. 2004 Dec 1;292(21):2655-7; discussion 2658-9. doi: 10.1001/jama.292.21.2655. Epub 2004 Nov 22. JAMA. 2004. PMID: 15572725 No abstract available.